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Clinical utility of RAS mutations in thyroid




RAS mutations play an important role in thyroid tumorigenesis. Considerable effort has been made in the last
decade to apply RAS mutations as molecular markers to the clinical management of thyroid nodules and thyroid
cancer. Yet, for the low diagnostic sensitivities and specificities of RAS mutations, when used alone, and for their
uncertain role in the clinical outcomes of thyroid cancer, it has been unclear how to appropriately use them to
assist the management of thyroid nodules and thyroid cancer. Studies from recent years, now added from the
Alexander group, have shed light on this issue, making a blurred clinical picture now emerge clearer—RAS
mutations, when combined with other genetic markers, have high diagnostic negative predictive values for thyroid
cancer; cytologically benign thyroid nodules, including those positive for RAS mutations, have long-term clinical
stability when non-surgically managed; and differentiated thyroid cancers harboring RAS mutations alone have an
excellent prognosis. This progress in understanding RAS mutations in thyroid cancer is showing a major impact on
molecular-based practice in the management of thyroid cancer.
Please see related research articles: http://dx.doi.org/10.1186/s12916-016-0554-1 and http://dx.doi.org/10.1186/
s12916-015-0419-z
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Background
The RAS oncogene plays a fundamental role in human
tumorigenesis [1]. Activating mutations in its three
proto-oncogenes—HRAS, KRAS and NRAS—are found
in nearly all human cancers. Thyroid cancer is one of
the earliest cases where activating RAS mutations were
discovered [2]. Today, the role of RAS oncogene in
thyroid tumorigenesis has been well established [3–5].
Mutations in RAS genes occur, on average, in 30–45 %
follicular thyroid cancer (FTC), 30–45 % follicular vari-
ant papillary thyroid cancer (FVPTC), 20–40 % poorly
differentiated thyroid cancer (PDTC), 10–20 % anaplas-
tic thyroid cancer, and rarely classical papillary thyroid
cancer (PTC). RAS mutations also occur in 20–25 %
benign follicular thyroid adenoma (FTA). Considerable
interest has been drawn to the potential clinical utility of
RAS mutations as diagnostic and prognostic molecular
markers, among other molecular markers, for thyroid
cancer [6]. Given these occurrence patterns in thyroid
tumors, however, RAS mutations themselves have low
diagnostic sensitivities and specificities. Also, the role of
RAS mutations in the clinical behavior of thyroid tumor
is uncertain. Consequently, the clinical picture of RAS
mutations in thyroid cancer has been a blurred one.
RAS mutations as diagnostic molecular markers for
thyroid nodules
Clinical management of thyroid cancer usually starts
with the evaluation of thyroid nodules, which is ex-
tremely common, with a prevalence of 50–70 % on
ultrasonography [7, 8]. The diagnostic mainstay of thy-
roid nodules is fine needle aspiration biopsy (FNAB). In
the last decade, much effort has been made to apply
RAS mutations as diagnostic molecular markers to
FNAB of thyroid nodules, particularly those with inde-
terminate cytology, which currently represents a major
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diagnostic challenge in clinical practice. Indeterminate
thyroid cytology includes three categories—atypia of un-
determined significance (AUS), follicular neoplasm (FN)
and suspicious for malignancy [9]. Surgical treatment for
thyroid nodules cytologically suspicious for malignancy
is generally accepted because of its high preoperative
malignancy probability (around 60–70 %) and the treat-
ment decision seems to be relatively easy to make. How
to treat AUS and FN, which have a moderate risk of ma-
lignancy (10–30 %), is a more challenging dilemma in
treatment decision making. Resolution of this dilemma
is believed to rely on the development of effective
diagnostic molecular marker-based tests [6]. An ideal
diagnostic molecular marker should have a 100 % or
near-100 % sensitivity and specificity. Yet, RAS muta-
tions have been proven to have inferior sensitivities and
specificities for thyroid cancer. An effective strategy to
apply RAS mutations to the diagnosis of thyroid cancer
is their combinational use with other molecular markers,
particularly genetic markers [6]. A prominent example is
the panel of genetic makers, including RAS mutations,
BRAF V600E mutation, RET/PTC and PAX8/PPARγ re-
arrangements, which, in a single-center unblinded study,
yielded increased diagnostic sensitivities for thyroid can-
cer in the indeterminate cytological setting to 88 % for
AUS and 87 % for FN [10]. The sensitivity of this test on
overall non-selected thyroid cytology was still high at
80 %, albeit lower, in a double-blinded multicenter study
[11]. The recently discovered TERT promoter mutations
[12] were shown to be diagnostically applicable to FNAB
[13]. Expansion of the genetic diagnostic panel to in-
clude additional genetic markers, including TERT pro-
moter mutations, has resulted in an improved sensitivity
for the FN category to 90 %, bringing the negative pre-
dictive value to 96 % [14]. Indeterminate thyroid cy-
tology consists mostly of follicular thyroid tumors and
the malignant types are mainly FTC and FVPTC, which
most commonly harbor RAS mutations. Therefore, RAS
mutations are an important component that helps make
the genetic panel diagnostically sensitive, propelling for
high negative predictive values. It is expected that as
the diagnostic efficiency of the genetic panel contain-
ing RAS mutations is confirmed and further improved,
ideally through large blinded multicenter optimizing
studies, it will become possible to use such a genetic
panel to help reliably rule out malignancy for thyroid
nodules.
RAS mutations in cytologically benign thyroid nodules
Since FTA is a main thyroid tumor in the indeterminate
cytology category and RAS mutations occur commonly
in FTA, albeit less frequently than FTC and FVPTC, use
of the diagnostic genetic panel is expected to result in a
large number of RAS mutation-positive but cytologically
benign or indeterminate thyroid nodules. How to appro-
priately manage these nodules has been unclear. Because
of the preferential occurrence of RAS mutations in
malignant over benign thyroid tumors and the estab-
lished oncogenic functions of RAS mutations in human
tumorigenesis, there is reasonable concern about the
prognosis of cytologically benign or indeterminate thy-
roid nodules harboring RAS mutations. Consequently,
some physicians may recommend surgical treatment for
all RAS mutation-positive thyroid nodules. Others, on
the other hand, may argue for non-surgical management
and conservative follow-up for RAS mutation-positive
but cytologically benign thyroid nodules, since non-
surgical management of cytologically benign thyroid
nodules is currently the standard management [15]. This
confusion is a result of the lack of knowledge of the clin-
ical behavior of such nodules in the long run.
The picture now becomes clearer with light shed by a
marvelous recent study from Medici et al. of the
Alexander group [16]. In this study, the authors investi-
gated the diagnostic value of RAS mutations on FNAB
for thyroid cancer and the clinical behavior of RAS
mutation-positive thyroid tumors. As expected, the au-
thors confirmed the low diagnostic sensitivity and speci-
ficity of RAS mutations when used alone. An important
novel finding, however, is that a group of RAS mutation-
positive but cytologically benign thyroid nodules that
were available for non-surgical management and conser-
vative monitoring all showed excellent stability without
radiographic growth or adverse clinical consequences
after a long-term clinical follow-up (mean 8.3 years).
This provides the first evidence that RAS mutation-
positive but cytologically benign thyroid nodules behave
as true benign nodules and can be conservatively man-
aged for long term. Given the expected rising number of
such patients in the coming years, long-term non-
surgical management of such nodules would likely have
many benefits, such as cost savings, avoidance of poten-
tial surgical complications and preservation of the
thyroid function. It should be noted, though, that the
prognosis of RAS-positive but cytologically benign thy-
roid nodules in an even longer term beyond the follow-
up time in the Medici et al. study remains unknown.
Further studies with longer follow-up durations are
needed to provide an even clearer picture. Also, the clin-
ical significance of RAS mutations in AUS/FN nodules
remains unclear.
Benign clinical prognosis of benign thyroid nodules
Consistent with the limited role of RAS mutations in be-
nign thyroid nodules discussed above, a recent publica-
tion in BMC Medicine by Medici et al., demonstrated
the safety of long-term conservative clinical follow-up of
cytologically benign thyroid nodules [17]. It has not been
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established how long benign thyroid nodules can be
safely and conservatively followed clinically. Repeat
evaluation of benign thyroid nodules at 1–2 years or
even shorter intervals is currently common practice.
This practice, however, has no direct evidence to sup-
port. In 1,254 patients with 1,819 cytologically benign
thyroid nodules, with a median time of 1.4 years to first
follow-up (ranging 0.5–14.1 years), the authors found no
difference in malignancy or mortality between various
follow-up intervals. Even though after three years of
follow-up, some benign thyroid nodules could grow and
even cause compressive symptoms requiring thyroidec-
tomy in certain cases, the authors did not identify a dif-
ference in risk of malignancy. The results support the
authors’ recommendation that the interval of repeat
evaluation can be safely extended to three years, redu-
cing the unnecessary visits and medical interventions.
This will likely have a profound impact on the healthcare
saving, given the large number of patients with benign
thyroid nodules. These findings by Medici et al. are con-
sistent with a recent Italian study similarly showing a
generally long-term stability and benign prognosis of
benign thyroid nodules [18]. These clinical findings also
again support the notion that RAS mutation alone plays
a limited role in the transformation of benign thyroid
nodules as many of such nodules expectedly harbor RAS
mutations [4].
RAS mutations as prognostic molecular markers for
thyroid cancer
Another important finding in the earlier Medici et al.
study [16] is that, even when histologically confirmed to
be malignant, the RAS mutation-positive tumors have
limited aggressiveness; these are usually FVPTC without
aggressive tumor behavior, such as extrathyroidal exten-
sion, lymph node metastasis and distant metastasis.
These tumors are highly curable and have an excellent
prognosis. This is in contrast to BRAF V600E mutation
[19–21] or TERT promoter mutations [12, 13, 22, 23],
which are associated with aggressiveness and poor clin-
ical outcomes of thyroid cancer. Medici et al. confirmed
the association of the BRAF V600E mutation with ag-
gressive behavior of thyroid cancer in their study [16].
These results are consistent with the previous findings
that, compared with the BRAF V600E mutation, RAS
mutations were associated with better differentiation of
thyroid cancer as reflected by normal or near-normal ex-
pression of thyroid iodide-handling genes in contrast to
the considerable down-regulation of these genes with
BRAF mutation [4, 24, 25]. Some studies showed an as-
sociation between poor tumor behavior and RAS muta-
tions in FTC [26] and PDTC [27, 28]. This likely reflects
the coexistence of RAS mutations with additional onco-
genic alterations, such as TERT promoter mutations;
RAS mutations and TERT promoter mutations are sig-
nificantly associated with each other in thyroid cancer
[29] and coexistence of the two types of mutations was
shown to be associated with a significantly higher tumor
recurrence compared with RAS mutation alone in FTC
[30], similar to the coexistence of BRAF V600E mutation
with TERT promoter mutations that is associated with
sharply increased aggressive clinicopathological behavior,
tumor recurrence and patient mortality in PTC [23, 31].
RAS mutation alone is most likely associated with lim-
ited aggressiveness of thyroid cancer. This concept is in
fact supported by a mouse model in which Kras muta-
tion alone caused only benign thyroid neoplasia and its
coexistence with Pten deletion in the PI3K pathway
caused transformation of the tumor into FTC with me-
tastasis [32].
One advantage of the expanded diagnostic genetic
panel is that it tests not only RAS mutations, but also
other important oncogenic genetic changes, including
TERT promoter mutations. Therefore, coexistence of
RAS mutations with additional oncogenic changes can
be identified using such a genetic panel; the result
should then be treated differently than finding RAS mu-
tation alone in terms of prognostic significance. If only
RAS mutations are found in differentiated thyroid can-
cer, it is reasonable and safe to assume a good prognosis.
Conclusions
Studies in recent years together with the studies by
Medici et al. [16, 17] have shed bright light on the role
of RAS mutations in the clinical behavior of thyroid tu-
mors and their value in assisting the management of
thyroid nodules and thyroid cancer, making a previously
blurred clinical picture now emerging clearer. Overall,
cytologically benign thyroid nodules, even when harbor-
ing RAS mutations, have an excellent prognosis and can
be safely and conservatively followed at relatively long
time intervals; differentiated thyroid cancer, when har-
boring RAS mutations alone without other coexisting
genetic alterations, generally lacks aggressive behaviors.
Given this advancement in understanding RAS muta-
tions, the following recommendations on their clinical
use as diagnostic and prognostic molecular markers may
be considered: 1) RAS mutations have an important
diagnostic value as a component of a genetic marker
panel that has high negative predictive values and can
thus help diagnostically rule out thyroid malignancy;
2) RAS mutation-positive but cytologically benign thyroid
nodules can be non-surgically managed and followed for
long term; 3) RAS mutation-positive differentiated thyroid
cancer has an excellent prognosis and can be treated with
less aggressive measures, e.g. hemithyroidectomy, in the
appropriate clinical settings; and 4) unless clinically
indicated otherwise, RAS mutation-positive AUS or FN
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thyroid nodules may be treated with hemithyroidectomy
and, if shown to be benign on additional molecular tests,
such as gene expression classifier [33], may be considered
to be non-surgically managed and conservatively followed.
These uses of RAS mutations as molecular markers are
applicable only when RAS mutation alone exists; if coex-
isting oncogenic genetic alterations are also found, such as
TERT promoter mutations or mutations in the PI3K path-
way, the tumor should be treated more aggressively in
appropriate clinical settings.
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